



July 16, 2020

Listing Department BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400001 Code: 532321

Code: CADILAHC

NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Re.: Press Release

Dear Sir / Madam,

Listing Department

Please find enclosed a Press Release dated July 16, 2020 titled "Zydus' receives supplemental Abbreviated New Drug Application (sANDA) approval from the USFDA for manufacturing of Doxycycline Injection at Jarod, Vadodara".

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors' at large.


Thanking you,

Yours faithfully, For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above





Zydus' receives supplemental Abbreviated New Drug Application (sANDA) approval from the USFDA for manufacturing of Doxycycline Injection at Jarod, Vadodara

Ahmedabad, July 16, 2020

Zydus Cadila has received approval for its supplemental Abbreviated New Drug Application (sANDA) for Doxycycline Injection USP, 100 mg/Vial from the US FDA. The product will be manufactured at Cadila Healthcare Ltd's injectable facility at Jarod, Vadodara (formerly known as Liva Pharmaceuticals Ltd). The state-of-the-art facility is equipped with manufacturing lines that can handle both liquid and lyophilised products based on vials and cartridges presentation.

Doxycycline USP is the first product approval at the second combined Liquid plus Lyophilised Vials Injectable line at the Jarod facility. This facility is an important one for Zydus' US Injectable portfolio as five ANDAs have been approved from this facility and another six have been filed, awaiting approval. Zydus has plans to file further ANDAs and NDAs from this facility. This approval will also help ramp up site transfer approvals from the Moraiya facility to this facility.

The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

For further information please contact : The Corporate Communications Department Cadila Healthcare Limited Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India. Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com CIN : L24230GJ1995PLC025878